Sigilon Therapeutics Inc (SGTX) Key Ratios
$22.47
$0.00 (0.00%)As on 18-Aug-2023 09:30EDT
Market cap
$56 Mln
Revenue (TTM)
$18 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 21.45 | 104.65 | 76.81 | -2.94 | -- |
| EBIT | 4.50 | 50.69 | 53.14 | 0.34 | -- |
| Net Profit | 0.04 | 48.79 | 55.73 | 0.83 | -- |
| EPS | -1,197.19 | -563.22 | 61.73 | 11.01 | -- |
| Book Value | -- | -- | -49.50 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -506.31 | -- | -171.75 | -337.35 | -787.96 |
| Net Margin
| -- | -- | -165.28 | -- | -- |
| Return on equity
| -101.75 | -- | -88.83 | -74.73 | -70.07 |
| Return on Capital
| -62.06 | -- | -- | -48.86 | -53.24 |
| Return on Assets
| -38.22 | -- | -26.70 | -37.52 | -42.36 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.72 | 0.43 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
--
|
-48.86
|
-53.24
|
-84.08
|
106.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-88.83
Lower than Peers by 48.49
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
-88.83
|
-74.73
|
-70.07
|
-160.44
|
78.29
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-26.70
Higher than Peers by 4.55
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
-26.70
|
-37.52
|
-42.36
|
-34.79
|
-56.40
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-171.75
Lower than Peers by 89.16
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
-171.75
|
-337.35
|
-787.96
|
-393.61
|
-311.71
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-165.28
Lower than Peers by 73.98
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
-165.28
|
-335.72
|
-815.04
|
-410.25
|
-314.86
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
76.81
Higher than Peers by 22.77
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
76.81
|
0.35
|
-0.28
|
-0.06
|
2.05
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
53.14
Higher than Peers by 54.16
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
53.14
|
42.27
|
-43.68
|
-19.31
|
-96.47
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
55.73
Higher than Peers by 63.26
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
55.73
|
44.46
|
-42.59
|
-23.11
|
-95.78
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
61.73
Higher than Peers by 47.50
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
61.73
|
0.45
|
0.42
|
-0.96
|
--
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
586.09
Higher than Peers by 596.22
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
586.09
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
--
|
0.72
|
0.43
|
0.25
|
-0.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.16
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
0.16
|
0.28
|
0.08
|
0.04
|
-0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.78
Lower than Peers by 4.03
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
1.78
|
2.40
|
3.62
|
4.34
|
1.91
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.77
Lower than Peers by 3.93
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
1.77
|
2.39
|
3.62
|
4.34
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-12.89
Lower than Peers by 10.81
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
-12.89
|
-19.07
|
-38.05
|
-43.80
|
-67.88
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
38.85
Higher than Peers by 19.83
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
38.85
|
26.72
|
0.61
|
1.32
|
0.96
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.16
Higher than Peers by 0.10
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
0.16
|
0.11
|
0.05
|
0.08
|
0.18
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
--
|
49.62
|
4.49
|
4.27
|
1.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
--
|
-0.26
|
-1.14
|
-11.58
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.25
Lower than Peers by 5.08
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
0.25
|
0.29
|
1.16
|
4.35
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.71
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
0.71
|
0.73
|
0.01
|
-8.97
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
56
Lower than Peers by 85
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Sigilon Therapeutics Inc (SGTX)
|
56
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|